February 2025
1. TANG H, Lu Y, Donahoo WT, Westen SC, et al
   Glucagon-Like Peptide-1 Receptor Agonists and Risk for Depression in Older Adults With Type 2 Diabetes : A Target Trial Emulation Study.
   Ann Intern Med. 2025 Feb 25. doi: 10.7326/ANNALS-24-01347.
   

   >> Share

   
   
2. LEUNG LB
   In nonseasonal depressive disorders, bright light therapy improves response and remission rates.
   Ann Intern Med. 2025;178:JC21.
   

   >> Share

   
   August 2024
3. WEI YJ, Winterstein AG, Schmidt S, Fillingim RB, et al
   Clinical and Adverse Outcomes Associated With Concomitant Use of CYP2D6-Metabolized Opioids With Antidepressants in Older Nursing Home Residents : A Target Trial Emulation Study.
   Ann Intern Med. 2024;177:1058-1068.
   

   >> Share

   
   
4. DOBRESCU AI, Persad E, Klerings I, Gartlehner G, et al
   Update Alert 2: Nonpharmacologic and Pharmacologic Treatments of Adult Patients With Major Depressive Disorder: A Systematic Review and Network Meta-Analysis for a Clinical Guideline by the American College of Physicians.
   Ann Intern Med. 2024;177:e2400428.
   

   >> Share

   
   
5. QASEEM A, Owens DK, Etxeandia-Ikobaltzeta I, Tufte JE, et al
   Nonpharmacologic and Pharmacologic Treatments of Adults in the Acute Phase of Major Depressive Disorder: A Living Clinical Guideline From the American College of Physicians (Version 1, Update Alert 2).
   Ann Intern Med. 2024;177:e2400593.
   

   >> Share

   
   April 2024
6. QASEEM A, Owens DK, Etxeandia-Ikobaltzeta I, Tufte JE, et al
   Nonpharmacologic and Pharmacologic Treatments of Adults in the Acute Phase of Major Depressive Disorder: A Living Clinical Guideline From the American College of Physicians (Version 1, Update Alert).
   Ann Intern Med. 2024;177:eL230440.
   

   >> Share

   
   
7. DOBRESCU AI, Persad E, Klerings I, Gartlehner G, et al
   Update Alert: Nonpharmacologic and Pharmacologic Treatments of Adult Patients With Major Depressive Disorder: A Systematic Review and Network Meta-analysis for a Clinical Guideline by the American College of Physicians.
   Ann Intern Med. 2024;177:eL230441.
   

   >> Share

   
   
8. QASEEM A, Andrews RA, Campos K, Goldzweig CL, et al
   Quality Indicators for Major Depressive Disorder in Adults: A Review of Performance Measures by the American College of Physicians.
   Ann Intern Med. 2024;177:507-513.
   

   >> Share

   
   January 2024
9. ISHIGUCHI H, Lip GYH
   In symptomatic AF, catheter ablation vs. medical therapy reduced depression and anxiety symptoms at 12 mo.
   Ann Intern Med. 2024 Jan 2. doi: 10.7326/J23-0105.
   

   >> Share

   
   September 2023
10. HOLSINGER T, Riordan P
    In treatment-resistant major depression, ketamine was noninferior to ECT for treatment response.
    Ann Intern Med. 2023 Sep 5. doi: 10.7326/J23-0068.
    

    >> Share

    
    February 2023
11. QASEEM A, Owens DK, Etxeandia-Ikobaltzeta I, Tufte J, et al
    Nonpharmacologic and Pharmacologic Treatments of Adults in the Acute Phase of Major Depressive Disorder: A Living Clinical Guideline From the American College of Physicians.
    Ann Intern Med. 2023;176:239-252.
    

    >> Share

    
    
12. GARTLEHNER G, Dobrescu A, Chapman A, Toromanova A, et al
    Nonpharmacologic and Pharmacologic Treatments of Adult Patients With Major Depressive Disorder: A Systematic Review and Network Meta-analysis for a Clinical Guideline by the American College of Physicians.
    Ann Intern Med. 2023;176:196-211.
    

    >> Share

    
    
13. AFFENGRUBER L, Wagner G, Dobrescu A, Toromanova A, et al
    Values and Preferences of Patients With Depressive Disorders Regarding Pharmacologic and Nonpharmacologic Treatments : A Rapid Review.
    Ann Intern Med. 2023;176:217-223.
    

    >> Share

    
    
14. DOBRESCU A, Chapman A, Affengruber L, Persad E, et al
    Cost-Effectiveness of First- and Second-Step Treatment Strategies for Major Depressive Disorder : A Rapid Review.
    Ann Intern Med. 2023;176:212-216.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share